Search

Your search keyword '"Keystone, E"' showing total 789 results
Start Over Author "Keystone, E"
789 results on '"Keystone, E"'

1. AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS

Author

Haranaka, M., primary, Eto, T., additional, Tanaka, T., additional, Yazawa, R., additional, Burmester, G. R., additional, Keystone, E., additional, Kim, S. H., additional, Bae, Y., additional, Suh, J., additional, Kim, Y., additional, Lee, J., additional, and Smolen, J. S., additional

Published
2024
Full Text
View/download PDF

2. OP0064 CHARACTERIZING PREVALENT NON-ARTICULAR PAIN AT EARLY RA DIAGNOSIS AND EVOLUTION OVER THE FIRST YEAR OF RA TREATMENT: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY

Author

Meng, C., primary, Lee, Y., additional, Schieir, O., additional, Valois, M. F., additional, Butler, M., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C. A., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bessette, L., additional, Pope, J., additional, Bartlett, S. J., additional, and Bykerk, V., additional

Published
2024
Full Text
View/download PDF

3. Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort

Author

Ahluwalia, V., Ahmad, Z., Akhavan, P., Albert, L., Alderdice, C., Aubrey, M., Aydin, S., Bajaj, S., Bell, M., Bensen, B., Bhavsar, S., Bobba, R., Bombardier, C., Bookman, A., Cabral, A., Carette, S., Carmona, R., Chow, A., Chow, S., Choy, G., Ciaschini, P., Cividino, A., Cohen, D., Dixit, S., Haaland, D., Hanna, B., Haroon, N., Hochman, J., Jaroszynska, A., Johnson, S., Joshi, R., Kagal, A., Karasik, A., Karsh, J., Keystone, E., Khalidi, N., Kuriya, B., Larche, M., Lau, A., LeRiche, N., Leung, Fe., Leung, Fr., Mahendira, D., Matsos, M., McDonald-Blumer, H., McKeown, E., Midzic, I., Milman, N.H., Mittoo, S., Mody, A., Montgomery, A., Mulgund, M., Ng, E., Papneja, T., Pavlova, P., Perlin, L., Pope, J., Purvis, J., Rohekar, G., Rohekar, S., Ruban, T., Samadi, N., Sandhu, S., Shaikh, S., Shickh, A., Shupak, R., Smith, D., Soucy, E., Stein, J., Thompson, A., Thorne, C., Wilkinson, S., Movahedi, Mohammad, Cesta, Angela, Li, Xiuying, and Bombardier, Claire

Published
2019
Full Text
View/download PDF

4. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

Author

Furst, Daniel E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, JWJ, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, and Mease, P J

Abstract

As in previous years, the consensus group to consider the use of biological agents was constituted by rheumatologists from the Universities of Erlangen, Leiden, and Vienna in Europe in cooperation with other Universities in the USA, Canada, and Europe. Pharmaceutical industry support was obtained from a number of companies, but these institutions had no part in the decisions about the specific programme or about the academic participants at this conference. The perspective of this consensus is from the treating physician’s point of view. The 128 rheumatologists and bioscientists who attended the consensus conference were chosen from a worldwide group of physicians and other scientists from 20 countries with expertise in the use of biological agents for the treatment of rheumatic diseases. The number of attendees and participants were limited so that not everyone who might have been interested could be invited. Additional information has come to light in the past year, corroborating the major positive effect these drugs have had in rheumatoid arthritis (RA) and other rheumatic diseases, as well as further documenting adverse events. Therefore an update of the previous consensus statement1 is appropriate. The consensus statement is annotated to document the credibility of the data supporting it as much as possible. This annotation is that of Shekelle et al2 and is described in appendix 3. As the number of possible references has become so large, sometimes reviews were used and, if they contained category A references, will be referred to as category A evidence. All participants reviewed relevant clinical published articles relating to tumour necrosis factor (TNF) and interleukin (IL)-1 blocking agents. They were given a draft consensus statement and were asked to revise the document in small discussion groups; open discussion of the revisions led to a final document, representing this updated consensus statement.

Published
2004

5. AB0402 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH EU-APPROVED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, TWO-ARM, SINGLE-DOSE STUDY IN HEALTHY SUBJECTS

Author

Yu, K. S., primary, Kim, B., additional, Shin, D., additional, Park, M. K., additional, Hwang, J. G., additional, Kim, M., additional, Chung, H., additional, Ghim, J., additional, Chung, J. Y., additional, Smolen, J. S., additional, Burmester, G. R., additional, Kim, S. H., additional, Bae, Y., additional, Jeon, D., additional, Yang, G., additional, Yoo, J., additional, Bae, J., additional, and Keystone, E., additional

Published
2023
Full Text
View/download PDF

6. POS0471 SPECIFIC SYMPTOM CLUSTERS AT DIAGNOSIS SIGNAL A POORER EARLY RA PROGNOSIS: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT

Author

Bartlett, S. J., primary, Bingham, C. O., additional, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Pope, J., additional, Bessette, L., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Hazlewood, G., additional, Keystone, E., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

7. POS0458 HAVING MORE TENDER THAN SWOLLEN JOINTS IS ASSOCIATED WITH WORSE FUNCTION, PAIN INTERFERENCE, SOCIAL PARTICIPATION AND OTHER HR-QOL OUTCOMES IN THE FIRST YEAR FOLLOWING RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT STUDY

Author

Meng, C., primary, Lee, Y., additional, Schieir, O., additional, Valois, M. F., additional, Butler, M., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bessette, L., additional, Pope, J., additional, Bartlett, S. J., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

8. POS0584-HPR PROS AND DISEASE ACTIVITY IN YEAR PRIOR TO COVID PREDICT TRAJECTORIES OF DEPRESSION IN ADULTS WITH RA IN FIRST 2 YEARS OF PANDEMIC: DATA FROM THE CANADIAN EARLY ARTHRITIS COHORT

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Pope, J., additional, Bessette, L., additional, Boire, G., additional, Hitchon, C., additional, Keystone, E., additional, Thorne, C., additional, Tin, D., additional, Hazlewood, G., additional, and Bykerk, V., additional

Published
2023
Full Text
View/download PDF

11. OP0308-HPR MORE THAN HALF OF RA PATIENTS WITH A LIFETIME HISTORY OF MOOD DISORDERS WERE ANXIOUS AND DEPRESSED DURING THE COVID-19 PANDEMIC: RESULTS FROM THE CANADIAN EARLY COHORT (CATCH) STUDY

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Hazlewood, G., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Pope, J., additional, Keystone, E., additional, Bessette, L., additional, and Bykerk, V., additional

Published
2022
Full Text
View/download PDF

13. AB0344 EFFICACY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) COMPARED WITH INTRAVENOUS INFLIXIMAB IN RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Author

Constantin, A., primary, Caporali, R., additional, Edwards, C. J., additional, Fonseca, J. E., additional, Iannone, F., additional, Keystone, E., additional, Schulze-Koops, H., additional, Kwon, T., additional, Kim, S., additional, Yoon, S., additional, Kim, D. H., additional, Park, G., additional, and Yoo, D., additional

Published
2022
Full Text
View/download PDF

16. Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort

Author

Ellingwood, L., Schieir, O., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Keystone, E. C., Tin, D., Thorne, C., Bykerk, V. P., Pope, J. E., Baron, Murray, Bessette, Louis, Boire, Gilles, Bykerk, Vivian, Colmegna, Ines, Fallavollita, Sabrina, Haaland, Derek, Haraoui, Paul, Hazlewood, Glen, Hitchon, Carol, Jamal, Shahin, Joshi, Raman, Keystone, Ed, Nair, Bindu, Panopoulos, Peter, Pope, Janet, Rubin, Laurence, Thorne, Carter, Villeneuve, Edith, and Zummer, Michel

Subjects
medicine.medical_specialty, lcsh:Diseases of the musculoskeletal system, business.industry, Swollen joints, General Medicine, Early rheumatoid arthritis, Original Articles, Logistic regression, Clinical disease, medicine.disease, Joint pain, Internal medicine, Cohort, Medicine, Original Article, Palindromic rheumatism, lcsh:RC925-935, medicine.symptom, business, Early arthritis
Abstract

Background This multicenter incident cohort aimed to characterize how often early rheumatoid arthritis (ERA) patients self‐report episodic joint inflammation (palindromic rheumatism) preceding ERA diagnosis and which characteristics differentiate these patients from those without prior episodic symptoms. Methods Data were from patients with early confirmed or suspected RA (more than 6 weeks and less than 12 months) enrolled in the Canadian Early ArThritis CoHort (CATCH) between April 2017 to March 2018 who completed study case report forms assessing joint pain and swelling prior to ERA diagnosis. Chi‐square and t tests were used to compare characteristics of patients with and without self‐reported episodic joint inflammation prior to ERA diagnosis. Multivariable logistic regression was used to identify sociodemographic and clinical measures associated with past episodic joint inflammation around the time of ERA diagnosis. Results A total of 154 ERA patients were included; 66% were female, and mean (SD) age and RA symptom duration were 54 (15) years and 141 (118) days. Sixty‐five (42%) ERA patients reported a history of episodic joint pain and swelling, half of whom reported that these symptoms preceded ERA diagnosis by over 6 months. ERA patients with past episodic joint inflammation were more often female, had higher income, were seropositive, had more comorbidities, fewer swollen joints, and lower Clinical Disease Activity Index (CDAI) around the time of ERA diagnosis (P < 0.05). These associations remained significant in multivariable regression adjusting for other sociodemographic and RA clinical measures. Conclusion Almost half of ERA patients experienced episodic joint inflammation prior to ERA diagnosis. These patients were more often female, had higher income, and presented with milder disease activity at ERA diagnosis.

Published
2019

20. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Author

Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, Bergna, M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi HJ, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, L, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, Ss, Cheah, C, Kan, S, Raja Mohamed RB, Selman, M, de Vries-Bouwstra JK, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena MC, Román Ivorra JA, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, SENSCIS Trial Investigators., Bergna M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi, Hj, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, Laura, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, S, Cheah, C, Kan, S, Raja Mohamed, Rb, Selman, M, de Vries-Bouwstra, Jk, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena, Mc, Román Ivorra, Ja, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., National Institute for Health Research, British Lung Foundation, University of Zurich, and Distler, Oliver

Subjects
Male, Vital capacity, Indoles, Vital Capacity, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, Pulmonary function testing, law.invention, oral, Idiopathic pulmonary fibrosis, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, SENSCIS Trial Investigators, CYCLOPHOSPHAMIDE, Clinical endpoint, scleroderma, 030212 general & internal medicine, Enzyme Inhibitors, 11 Medical and Health Sciences, lung diseases, Lung Diseases, Interstitial -- drug therapy -- etiology -- physiopathology, 10051 Rheumatology Clinic and Institute of Physical Medicine, General Medicine, respiratory system, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, MANIFESTATIONS, Disease Progression, Nintedanib, Female, TYROSINE KINASE INHIBITOR, Life Sciences & Biomedicine, CLINICAL-TRIALS, Adult, Diarrhea, medicine.medical_specialty, FIBROBLASTS, 610 Medicine & health, Placebo, administration, behavioral disciplines and activities, 03 medical and health sciences, FEV1/FVC ratio, Medicine, General & Internal, Double-Blind Method, Internal medicine, General & Internal Medicine, Enzyme Inhibitors -- adverse effects -- therapeutic use, SCORE, medicine, Humans, Indoles -- adverse effects -- therapeutic use, Scleroderma, Systemic -- complications -- drug therapy, Science & Technology, Scleroderma, Systemic, Protein-Tyrosine Kinases -- antagonists & inhibitors, business.industry, MORTALITY, interstitial, PULMONARY-FUNCTION, systemic, STANDARDIZATION, medicine.disease, EFFICACY, respiratory tract diseases, body regions, chemistry, adult, diarrhea, disease progression, double-blind method, enzyme inhibitors, female, humans, indoles, lung diseases, interstitial, male, middle aged, protein-tyrosine kinases, scleroderma, systemic, vital capacity, business, Lung Diseases, Interstitial, Diarrhea -- chemically induced
Abstract

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD., info:eu-repo/semantics/published

Published
2019

23. AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT

Author

Furst, D., primary, Keystone, E., additional, Kay, J., additional, Jaworski, J., additional, Wojciechowski, R., additional, Wiland, P., additional, Dudek, A., additional, Krogulec, M., additional, Jeka, S., additional, Zielinska, A., additional, Trefler, J., additional, Bartnicka-Masłowska, K., additional, Krajewska-Wlodarczyk, M., additional, Klimiuk, P., additional, Lee, S. J., additional, Kim, S. H., additional, Bae, Y., additional, Yang, G., additional, Yoo, J., additional, and Kim, T., additional

Published
2021
Full Text
View/download PDF

26. OP0262-HPR THE NEURO-QOL UPPER EXTREMITY FUNCTION SCALE: NEW OPPORTUNITIES TO MORE RELIABLY AND PRECISELY MEASURE SELF-REPORTED HAND FUNCTION AND SELF-CARE ACTIVITIES IN PEOPLE WITH RA

Author

Bartlett, S. J., primary, Schieir, O., additional, Valois, M. F., additional, Boire, G., additional, Pope, J., additional, Keystone, E., additional, Thorne, C., additional, Tin, D., additional, Hitchon, C., additional, Bessette, L., additional, Hazlewood, G., additional, and Bykerk, V., additional

Published
2021
Full Text
View/download PDF

28. POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT

Author

Hadwen, B., primary, Stranges, S., additional, Klar, N., additional, Bindee, K., additional, Pope, J., additional, Bartlett, S. J., additional, Boire, G., additional, Bessette, L., additional, Hitchon, C., additional, Hazlewood, G., additional, Keystone, E., additional, Schieir, O., additional, Thorne, C., additional, Tin, D., additional, Valois, M. F., additional, Bykerk, V., additional, and Barra, L., additional

Published
2021
Full Text
View/download PDF

30. POS0222 PREDICTORS OF RESPONSE: BASELINE CHARACTERISTICS AND EARLY TREATMENT RESPONSES ASSOCIATED WITH ACHIEVEMENT OF REMISSION AND LOW DISEASE ACTIVITY AMONG UPADACITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Kavanaugh, A., primary, Szekanecz, Z., additional, Keystone, E. C., additional, Rubbert-Roth, A., additional, Hall, S., additional, Xavier, R., additional, Polido-Pereira, J., additional, Song, I. H., additional, Martin, N., additional, Song, Y., additional, Anyanwu, S., additional, and Nash, P., additional

Published
2021
Full Text
View/download PDF

32. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

Author

Strand, V., Heijde, D. van der, Tanaka, Y., Keystone, E., Kremer, J., Zerbini, C.A.F., Cardiel, M.H., Cohen, S., Nash, P., Song, Y.W., Tegzova, D., Gruben, D., Wallenstein, G., Connell, C.A., Fleischmann, R., and ORAL Scan Investigators

Subjects
rheumatoid arthritis, tofacitinib, methotrexate, patient-reported outcome measures
Abstract

ObjectiveTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan (NCT00847613), which evaluated the impact of tofacitinib on patient-reported outcomes (PROs) through 24 months in patients with active RA and inadequate responses to methotrexate (MTX-IR).MethodsPatients were randomised 4:4:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID), or placebo advanced to tofacitinib 5 or 10 mg, plus background MTX. Patients receiving placebo advanced to tofacitinib at month 3 (non-responders) or month 6 (remaining patients). Mean changes from baseline in PROs, assessed at months 1-24, included Health Assessment Questionnaire-Disability Index, Patient Global Assessment of disease activity (visual analogue scale [VAS]), Patient Assessment of Arthritis Pain (VAS), health-related quality of life (Short Form-36 version 2), Functional Assessment of Chronic Illness Therapy-Fatigue and Medical Outcomes Study-Sleep.ResultsOverall, 539/797 ( 67.6%) patients completed 24 months' treatment. At month 3, tofacitinib-treated patients reported significant (p

Published
2020

33. Efficacité et tolérance du filgotinib chez les patients atteints de polyarthrite rhumatoïde (PR) présentant une réponse inadéquate au méthotrexate (RI-MTX) : résultats de l’étude FINCH 1 à 52 semaines

Author

Combe, B., primary, Kivitz, A., additional, Tanaka, Y., additional, Van Der Heijde, D., additional, Simon Campos, J.-A., additional, Baraf, H., additional, Kumar, U., additional, Matzkies, F., additional, Bartok, B., additional, Ye, L., additional, Guo, Y., additional, Tasset, C., additional, Sundy, J., additional, Jahreis, A., additional, Mozzafarian, N., additional, Landewé, R., additional, Bae, S.C., additional, Keystone, E., additional, and Nash, P., additional

Published
2020
Full Text
View/download PDF

38. FRI0030 MORE THAN HALF OF NEWLY DIAGNOSED RA PATIENTS ARE NOT CONVINCED OF THE NECESSITY OF RA MEDICINES: ASSOCIATIONS WITH RA CHARACTERISTICS, SYMPTOMS, AND FUNCTION IN THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)

Author

Ta, V., primary, Schieir, O., additional, Valois, M. F., additional, Hazlewood, G., additional, Hitchon, C., additional, Bessette, L., additional, Tin, D., additional, Thorne, C., additional, Pope, J., additional, Boire, G., additional, Keystone, E., additional, Bykerk, V., additional, and Bartlett, S. J., additional

Published
2020
Full Text
View/download PDF

40. THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS

Author

Combe, B., primary, Kivitz, A., additional, Tanaka, Y., additional, Van der Heijde, D., additional, Simon-Campos, J. A., additional, Baraf, H. S. B., additional, Kumar, U., additional, Matzkies, F., additional, Bartok, B., additional, Ye, L., additional, Guo, Y., additional, Tasset, C., additional, Sundy, J., additional, Jahreis, A., additional, Mozaffarian, N., additional, Landewé, R. B. M., additional, Bae, S. C., additional, Keystone, E., additional, and Nash, P., additional

Published
2020
Full Text
View/download PDF

43. SAT0053 ESTIMATING REAL-WORLD UNMET NEEDS FOR REACHING REMISSION IN THE FIRST YEAR FOLLOWING EARLY RA DIAGNOSIS: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)

Author

Schieir, O., primary, Bartlett, S. J., additional, Valois, M. F., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Pope, J., additional, Thorne, C., additional, Tin, D., additional, and Bykerk, V., additional

Published
2020
Full Text
View/download PDF

45. FRI0032 REGIONAL AND WIDESPREAD PATTERNS OF NON-ARTICULAR PAIN ARE COMMON AT RA DIAGNOSIS AND CONTRIBUTE TO POOR OUTCOMES AT 12 MONTHS: A PROSPECTIVE STUDY OF PAIN PATTERNS IN CANADIANS WITH RA

Author

Bykerk, V., primary, Schieir, O., additional, Valois, M. F., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Pope, J., additional, and Bartlett, S. J., additional

Published
2020
Full Text
View/download PDF

49. SAT0127 REAL-WORLD PREDICTORS OF STARTING DIFFERENT ADVANCED DMARD TREATMENTS IN RHEUMATOID ARTHRITIS: A PROSPECTIVE INVESTIGATION FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH) GROUP

Author

Weiler, M., primary, Schieir, O., additional, Valois, M. F., additional, Bartlett, S. J., additional, Bessette, L., additional, Boire, G., additional, Hazlewood, G., additional, Hitchon, C., additional, Keystone, E., additional, Tin, D., additional, Thorne, C., additional, Bykerk, V., additional, and Pope, J., additional

Published
2020
Full Text
View/download PDF

50. P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis

Author

Besuyen, R, primary, Walker, D, additional, Winthrop, K, additional, Genovese, M, additional, Combe, B, additional, Tanaka, Y, additional, Kivitz, A, additional, Matzkies, F, additional, Bartok, B, additional, Ye, L, additional, Guo, Y, additional, Tasset, C, additional, Sundy, J, additional, Keystone, E, additional, Westhovens, R, additional, Rigby, W, additional, and Burmester, G, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results